RABBIT is financially supported by a joint grant from all companies that provide biologic DMARDs for therapy of rheumatoid arthritis. The sponsorship is unconditional; therefore, solely the principle investigators and the scientific advisory board are responsible for data acquisition and analysis as well as for publication of results; the drug manufacturers have no influence over this.
| AbbVie Deutschland GmbH & Co. KG |
| Amgen GmbH |
| Biocon Biologics Germany GmbH |
| Bristol-Myers Squibb GmbH & Co. KGaA |
| Celltrion Inc. |
| Fresenius Kabi SwissBioSim GmbH |
| Hexal AG |
| Lilly Deutschland GmbH |
| MSD Sharp & Dohme GmbH |
| MYLAN S.A.S. |
| Pfizer Pharma GmbH |
| Roche Pharma AG |
| Samsung Bioepis Co., Ltd. |
| Sanofi-Aventis Deutschland GmbH |
| Swedish Orphan Biovitrum (vorher Amgen) (bis 2012) |
| UCB Biosciences GmbH |
